Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Biosyngen Approved for US Trials of TCR-T Candidate for Solid Tumor Cancers

publication date: Sep 11, 2023

Biosyngen, a Singapore-Guangzhou cell therapy company, was green-lighted to begin a US Phase I/II clinical trial of its first T-cell receptor-engineered targeted (TCR-T) product for lung cancer, gastric cancer and other advanced solid tumors. The approval for BRL03 is the company's third first-in-class therapy and its first self-developed candidate to start clinical trials. Biosyngen is currently filing an IND application for BST02, a tumor-infiltrating lymphocyte (TIL) molecule. When BRL03 is approved, the company will have clinical-stage assets in all three major T-cell therapy types -- CAR-T, TCR-T and TIL. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital